{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:28:32Z","timestamp":1791217712512,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:00:00Z","timestamp":1458172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13181-016-0543-y","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T13:50:50Z","timestamp":1458309050000},"page":"305-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A RANKL Wrinkle: Denosumab-Induced Hypocalcemia"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-1164","authenticated-orcid":false,"given":"Larissa K.","family":"Laskowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Howland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Kavcsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Lugassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silas W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"key":"543_CR1","doi-asserted-by":"crossref","unstructured":"Amgen Inc. Prolia [package insert]. 2015 Mar 2;1\u201331.","DOI":"10.1353\/atj.2014.0051"},{"key":"543_CR2","unstructured":"Amgen Inc. Xgeva [package insert]. 2014 Dec 5;1\u201320."},{"key":"543_CR3","first-page":"565393","volume":"2014","author":"M Muqeet Adnan","year":"2014","unstructured":"Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S. Severe hypocalcemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol. 2014;2014:565393.","journal-title":"Case Rep Nephrol"},{"key":"543_CR4","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.clgc.2014.11.008","volume":"13","author":"KA Autio","year":"2015","unstructured":"Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, Barr HC, et al. Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians. Clin Genitourin Cancer. 2015;13:e305\u20139.","journal-title":"Clin Genitourin Cancer"},{"key":"543_CR5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1185\/03007995.2013.813840","volume":"29","author":"W-X Qi","year":"2013","unstructured":"Qi W-X, Lin F, He A-N, Tang L-N, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin. 2013;29:1067\u201373.","journal-title":"Curr Med Res Opin"},{"key":"543_CR6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66:1139\u201346.","journal-title":"Int J Clin Pract"},{"key":"543_CR7","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875\u201382.","journal-title":"J Clin Oncol"},{"key":"543_CR8","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564\u201371.","journal-title":"J Clin Oncol"},{"key":"543_CR9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TLJ, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745\u201355.","journal-title":"N Engl J Med"},{"key":"543_CR10","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132\u20139.","journal-title":"J Clin Oncol"},{"key":"543_CR11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322.","journal-title":"Lancet"},{"key":"543_CR12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125\u201332.","journal-title":"J Clin Oncol"},{"key":"543_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39\u201346.","journal-title":"Lancet"},{"key":"543_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","volume":"39","author":"P Peddi","year":"2013","unstructured":"Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97\u2013104.","journal-title":"Cancer Treat Rev"},{"key":"543_CR15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471\u20139.","journal-title":"J Bone Miner Res"},{"key":"543_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","volume":"78","author":"W Sohn","year":"2014","unstructured":"Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol. 2014;78:477\u201387.","journal-title":"Br J Clin Pharmacol"},{"key":"543_CR17","first-page":"259","volume":"3","author":"RF Njoh","year":"2013","unstructured":"Njoh RF, Nguyen A, Sadigh M. Cisplatin induced hypomagnesemic hypocalcemia: a case report and a review of the pathophysiology. J Clin Case Rep. 2013;3:259.","journal-title":"J Clin Case Rep"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-016-0543-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-016-0543-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-016-0543-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T14:08:01Z","timestamp":1567692481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-016-0543-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["543"],"URL":"https:\/\/doi.org\/10.1007\/s13181-016-0543-y","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]}}}